US 11291659
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted A61KA61K31/00A61K31/416
Quick answer
US patent 11291659 (P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD) held by Fulcrum Therapeutics, Inc. expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fulcrum Therapeutics, Inc.
- Grant date
- Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/00, A61K31/416, A61K31/437, A61K31/4418